Digital patient profiles and the extensive use of real-world data are significantly impacting the landscape of oncology clinical trials, as highlighted by Gen Li, PhD, MBA, the president and founder of Phesi. These innovative tools are revolutionizing trial design, enhancing patient recruitment precision, and mitigating the risks associated with trial failures.
Phesi’s analysis reveals the abundance of real-world data available for various cancers such as colorectal, breast, and lung. The trial accelerator platform developed by Phesi serves as a critical tool in translating this data into more intelligent trial designs and facilitating more accurate patient recruitment strategies. By tapping into a vast pool of over 106 million patient records, the platform enables alignment checks between actual patient profiles and trial designs, thereby pinpointing areas for improvement in inclusion/exclusion criteria, outcome measures, and treatment duration.
The creation of digital patient profiles allows for a comprehensive evaluation of trial designs against real patient data and aids in refining the operational feasibility of the trials. The platform’s ability to transform these profiles into digital twins of patients at the baseline level enhances the accuracy of recruitment and evaluation processes, eliminating the need for frequent protocol amendments that were common in the past. Furthermore, utilizing digital twins to simulate control arms and project safety and efficacy outcomes offers a valuable alternative to conducting traditional trials, particularly beneficial for smaller-scale clinical studies.
The continual expansion of Phesi’s database to include diverse patient footprints from various sources and study designs enhances the statistical robustness and minimizes biases in data analysis. This inclusive approach not only strengthens the confidence in the data but also enables the study of rare diseases and biomarkers that were previously underexplored. By constructing digital patient profiles for even rare cases, such as male patients with specific biomarkers in cancer, Phesi’s platform empowers researchers to design more effective and ethical trials while maintaining stringent controls to safeguard patient well-being.
Key Takeaways:
– Real-world data and digital patient profiles are reshaping oncology clinical trials by optimizing trial designs and enhancing patient recruitment accuracy.
– The use of digital twins derived from patient profiles offers a virtual alternative to control arms, improving trial efficiency and precision.
– Phesi’s expansive database, now exceeding 167 million patients, enables the study of rare diseases and biomarkers, leading to more inclusive and robust clinical trial planning.
– Leveraging these advanced tools not only enhances the success rates of clinical trials but also ensures a more ethical and patient-centric approach to trial design and execution.
Read more on ajmc.com